INTRODUCTION
The ability to rapidly respond to changes in energy levels is essential for cells and organisms. AMPK plays a central role in the maintenance of energy homeostasis (Kahn et al., 2005) and has been implicated in longevity and tumor suppression (Apfeld et al., 2004; Greer et al., 2007a; Mair et al., 2011; Shackelford and Shaw, 2009) . AMPK is a conserved heterotrimeric serine/threonine protein kinase composed of a catalytic a subunit, a scaffolding b subunit, and a regulatory g subunit. AMPK is activated by a range of stimuli, including nutrient deprivation, exercise, antidiabetic drugs, and cellular stresses, which lead to an increase in the AMP:ATP ratio (Kahn et al., 2005) . AMP binding to the g subunit activates AMPK by allosterically activating the kinase and facilitating phosphorylation by upstream kinases (Hardie et al., 1999; Hawley et al., 2005) , and by inhibiting dephosphorylation by protein phosphatases (Sanders et al., 2007b) .
Once activated, AMPK phosphorylates a number of substrates involved in metabolic regulation, including acetylCoA carboxylase 1 (ACC1), to induce ATP production and restore energy levels (Witters and Kemp, 1992; Woods et al., 1994) . AMPK also phosphorylates several proteins in the TOR signaling pathway, including TSC2 (Inoki et al., 2003) and Raptor (Gwinn et al., 2008) , resulting in the inhibition of protein translation, a high energy-consuming pathway. AMPK regulates gene expression through the phosphorylation of transcription factors (e.g., FOXO3 [Greer et al., 2007b] ), coactivators (e.g., CRTC2 Shaw et al., 2005] ), histone deacetylases (Mihaylova et al., 2011) , and histones (Bungard et al., 2010) . AMPK has been proposed to promote cell-cycle arrest at the G1 phase via phosphorylation of tumor suppressors such as p53 (Imamura et al., 2001; Jones et al., 2005) , Rb (Dasgupta and Milbrandt, 2009) , and p27
Kip1 (Liang et al., 2007) , although the phosphorylation site in some of these substrates diverges from the AMPK consensus motif (Gwinn et al., 2008) . Emerging evidence suggests that AMPK might also regulate mitosis in Drosophila and human cells (Bettencourt-Dias et al., 2004; Dasgupta and Milbrandt, 2009; Lee et al., 2007; Vazquez-Martin et al., 2009a , 2009c . However, the exact nature of AMPK's role in mitotic progression and the mechanisms by which AMPK might control mitosis are not known. Identifying substrates of AMPK in a systematic manner is a key step in understanding the cellular processes controlled by this energy-sensing protein kinase. Here we used a chemical genetic screen to identify direct in vivo substrates of one of the catalytic subunits of AMPK, AMPKa2, in human cells. We discovered 28 previously unidentified AMPK substrates that are enriched for proteins involved in chromosomal segregation, mitosis, cytokinesis, and cytoskeletal reorganization. We focused on two substrates, protein phosphatase 1 regulatory subunit 12C (PPP1R12C) and p21-activated protein kinase (PAK2), because they are both involved in the regulation of myosin regulatory light chain (MRLC), a crucial protein for mitotic progression. We found that AMPK is important for the phosphorylation of PPP1R12C and PAK2 in cells. Phosphorylation of PPP1R12C by AMPK is required for 14-3-3 binding and complete induction of MRLC phosphorylation. Both AMPK activity and phosphorylation of PPP1R12C are elevated during mitosis and are important for mitotic progression. Thus, AMPK coordinates a network of proteins involved in mitosis completion, which may be essential for normal development, stem cell self-renewal, and cancer progression.
RESULTS
An Analog-Specific Mutant of AMPKa2 Can Use Bulky ATP Analogs To identify direct substrates of AMPKa2 in vivo, we used a chemical genetics approach (Alaimo et al., 2001 ). This approach is based on the fact that the ATP-binding pocket of protein kinases contains a conserved ''gatekeeper residue'' in close contact with the N 6 position of the adenine ring of ATP. Replacement of this gatekeeper residue with a smaller amino acid enables the mutant protein kinase (termed ''analog-specific'') to use ATP analogs containing bulky groups at the N 6 position (Allen et al., 2007) ( Figure 1A ). In contrast, the bulky ATP analogs are poor substrates for wild-type (WT) kinases due to the steric hindrance of the gatekeeper residue. N 6 -modified ATPgS nucleotides are also accepted by the analog-specific kinase, and the transferred thiophosphate can be alkylated and recognized by a specific monoclonal antibody ( Figure 1A ) (Allen et al., 2005 (Allen et al., , 2007 . This chemical genetic approach allows specific labeling of direct substrates of a protein kinase in cells. Alignment of the amino acid sequence of human AMPKa2 with that of other protein kinases for which analog-specific versions have been successfully generated revealed that methionine 93 is likely the gatekeeper residue of AMPKa2 ( Figure 1B ). To generate an analog-specific version of AMPKa2 (AS-AMPKa2), we mutated methionine 93 to a glycine residue. We then tested the in vitro kinase activity of WT and AS-AMPKa2 by incubating these kinases with recombinant GST-FOXO3, a known AMPK substrate (Greer et al., 2007b) , in the presence of ATPgS or a variety of N 6 -substituted forms of ATPgS. WT-AMPKa2 uses ATPgS to phosphorylate GST-FOXO3 but is unable to use N 6 -modified bulky forms of ATPgS ( Figure 1C ).
In contrast, AS-AMPKa2 phosphorylates FOXO3 to a lesser extent than WT-AMPKa2 using ATPgS, but is able to use the N 6 -substituted bulky forms of ATPgS, particularly N 6 -(phenethyl)
ATPgS, to phosphorylate FOXO3 in vitro ( Figure 1C ). Thus, methionine 93 is the gatekeeper residue in AMPKa2, and mutation of this residue to a glycine allows AMPKa2 to use bulky analogs of ATP in vitro.
In Vivo Labeling of Known AMPK Substrates by AS-AMPKa2
We asked if AS-AMPKa2 could directly phosphorylate substrates in cells under relatively physiological conditions. To this end, we expressed HA-tagged versions of WT-AMPKa2 or AS-AMPKa2, together with the b1 and g1 subunits, as well as several known M2 (Flag)-tagged AMPK substrates in 293T cells and stimulated AMPK activity by serum starvation and addition of 2-deoxyglucose (2DG). N 6 -(phenethyl) ATPgS was added in the presence of digitonin, a mild detergent that permeabilizes the plasma membrane to allow the N 6 -(phenethyl) ATPgS to enter cells while largely preserving other intracellular compartments. Importantly, these conditions of in vivo labeling preserved endogenous AMPK signaling (see Figure S1A available online), although they led to higher AMPK activation than glucose starvation, a physiological way of activating AMPK (Figure S1B) . To test if substrates could be directly phosphorylated by AS-AMPKa2 in cells, known AMPK substrates were immunoprecipitated using an antibody to the M2 tag, and the immune complexes were analyzed by western blot using the thioP antibody. These experiments confirmed that AS-AMPKa2 phosphorylates known substrates of AMPK such as CRTC2, TSC2, and FOXO3 in cells ( Figure 1D ). Not all proteins that are highly overexpressed were phosphorylated by AS-AMPKa2 (e.g., SIRT2) ( Figure 1D ), indicating that AS-AMPKa2 is relatively specific for its substrates. Some substrates (e.g., CRTC2) were also labeled to a minor extent in cells expressing WT-AMPKa2 ( Figure 1D ), suggesting that either WT-AMPKa2 or an endogenous kinase is able to use N 6 -(phenethyl) ATPgS to phosphorylate some substrates, albeit to a much lower extent than AS-AMPKa2. Mutating the gatekeeper site in AMPKa2 does not significantly alter AMPKa2 site specificity, as a form of FOXO3 in which all six residues known to be phosphorylated by AMPK were mutated to alanines (6A FOXO3) (Greer et al., 2007b) was no longer phosphorylated by AS-AMPKa2 in cells ( Figure 1E ). Moreover, endogenous FOXO3 was also phosphorylated by AS-AMPKa2 ( Figure 1F ). Finally, specific labeling of FOXO3 was observed in a stable cell line with more physiological levels of AS-AMPKa2 and with endogenous levels of b and g subunits ( Figure S1C ). Thus, this chemical genetic approach is an effective method for identifying direct endogenous substrates of AMPKa2 in a relatively physiological cellular context.
Screen for Direct AMPKa2 Substrates In Vivo Using AS-AMPKa2
To identify previously unidentified AMPKa2 substrates, we expressed WT-AMPKa2 or AS-AMPKa2 together with the b1 and g1 subunits in 293T cells (Figure 2A ). After activation of AMPK by serum starvation and 2DG, in vivo phosphorylation with N 6 -(phenethyl) ATPgS was performed. We used the thioP antibody to immunoprecipitate the alkylated protein products of the in vivo phosphorylation. The immunoprecipitated proteins were resolved by SDS-PAGE and analyzed by western blot. More proteins were labeled in cells expressing the AS-AMPKa2 than WT-AMPKa2, both before and after immunoprecipitation ( Figure 2B ), indicating that a number of proteins were specifically phosphorylated by AS-AMPKa2. The entire lanes of proteins immunoprecipitated from cells expressing WT-AMPKa2 and AS-AMPKa2 were cut, the proteins extracted from these strips were digested with trypsin, and the identity of the resulting peptides was determined by tandem mass spectrometry (Figure 2A) . Due to the abundance of peptides from the heavy and light chains of IgG, only proteins with a molecular weight higher than the IgG heavy chain (55 kDa) were analyzed. Two independent biological replicates were performed ( Figure 2C ). We focused on proteins for which at least 10-fold more peptides were identified in cells expressing AS-AMPKa2 compared to cells expressing WT-AMPKa2. Using this stringent cutoff, we identified 98 different proteins in the first experiment and 177 different proteins in the second experiment that were labeled specifically by AS-AMPKa2 ( Figure 2C ; Table S1 ). Thirty-two proteins were identified in both biological replicates (Table 1) , thereby representing the most likely direct substrates of AMPKa2 in this screen. Among these 32 proteins are three previously known substrates of AMPK: ACC1 (Witters and Kemp, 1992; Woods et al., 1994) , CRTC2 Shaw et al., 2005) , and kinesin light chain 1 (McDonald et al., 2009) (Table 1) . We also identified AMPKa2 as an autophosphorylation substrate, which has been previously reported (Woods et al., 2003) , although it may also be due to the fact that ASAMPKa2 was overexpressed. Not all known AMPK substrates were found (e.g., TSC2, FOXO3, Raptor), possibly due to low abundance of some proteins or to molecular weights lower than 55 kDa. Overall, these results indicate that this chemical genetic screen is sensitive enough to identify previously known AMPK substrates. To confirm that the proteins identified in the chemical genetic screen were indeed substrates of AMPK, we tested seven of them (protein phosphatase 1 regulatory subunit 12A [PPP1R12A], PPP1R12C, PAK2, CDC27, brain-specific angiogenesis inhibitor 1-associated protein 2 [BAIAP2], gephyrin [GPHN] , and CARM1) using the candidate-based approach in cells described in Figure 1D . Six of these seven proteins were specifically labeled by AS-AMPKa2 ( Figure 2D ), indicating that they are direct substrates of AMPKa2 in human cells. CARM1 was the only protein that was not labeled by AS-AMPKa2 in the validation of the screen ( Figure 2D ), possibly because it was coprecipitated with a yet-to-be-identified substrate of AMPKa2.
To confirm that these substrates are phosphorylated directly by AMPK, we performed in vitro kinase assays using WT-AMPK (a mixture of AMPKa1-and -a2-containing complexes) purified from rat liver, g 32 P-ATP, and recombinant substrates purified from E. coli. PPP1R12A, PPP1R12C, PAK2, CDC27, and BAIAP2 were all phosphorylated in vitro by WT-AMPK ( Figures 2E, 3E , and 3G), although CARM1 was not ( Figure S2 ), providing additional evidence that PPP1R12A, PPP1R12C, PAK2, CDC27, and BAIAP2 are direct substrates of AMPK. The fact that these proteins are phosphorylated by WT-AMPK also confirms that their identification in the chemical genetic screen is unlikely to have resulted from altered substrate specificity of AS-AMPKa2. Thus, the chemical genetic screen is an effective approach for the identification of direct substrates of AMPKa2 in cells, and could be used for other protein kinases.
AMPKa2 Substrates Are Enriched for Proteins Involved in Mitosis
Global analysis of AMPKa2 substrates identified in either biological replicate of our screen using GO, GSEA, and PANTHER revealed that these AMPK substrates displayed a significant enrichment for proteins involved in cell cycle, particularly mitosis and chromosomal segregation ( Figure 2F ; Table S2 and Table S3 ). The enrichment for M phase was still highly significant even when the comparison list was restricted to proteins larger than 55 kDa ( Figure 2G ; Table S4 ). These observations raise the intriguing possibility that AMPKa2 may coordinate different aspects of mitosis in cells. For example, APC1 and CDC27 are two components of the anaphase-promoting complex (Peters, 2006) . PPP1R12A/MYPT1, PPP1R12B/ MYPT2, and PPP1R12C/MBS85 are known to inhibit the activity of the MRLC (Ito et al., 2004) , a protein that regulates cytokinesis (Komatsu et al., 2000) . The protein kinase PAK2 activates MRLC by direct phosphorylation and is involved in cytoskeletal reorganization (Tuazon and Traugh, 1984) . Finally, BAIAP2 is a protein required for actin-myosin-dependent processes and motility (Chauhan et al., 2009 ). Thus, AMPKa2 may regulate a network of substrates to coordinate chromosomal segregation, mitosis, cytokinesis, and cytoskeletal reorganization. (Allen et al., 2007; Niswender et al., 2002; Polson et al., 2001; Ubersax et al., 2003; Ventura et al., 2006; Weiss et al., 2000) . 
Identification of AMPK Phosphorylation Sites in Four AMPKa2 Substrates
We identified the specific residues phosphorylated by AMPKa2 in PPP1R12C, BAIAP2, CDC27, and PAK2. Analysis of these proteins using Scansite with an optimized AMPK phosphorylation consensus motif derived from Gwinn et al. (2008) revealed residues that conformed to the AMPK consensus motif in each substrate ( Figure 3A ). We mutated these sites to nonphosphorylatable alanines and determined the extent of phosphorylation of each mutant using the candidate-based in vivo labeling method. Using this approach for PPP1R12C, BAIAP2, and CDC27, we found that mutation (C) Results of two independent labeling and substrate isolation experiments. Red and blue circles represent proteins found in cells expressing WT-AMPKa2 and AS-AMPKa2, respectively. The numbers indicate the number of proteins identified in each category. The full list of proteins identified in each biological replicate is provided in Table S1 . Table S2 and Table S3 .
(G) Selected GO terms for AMPK substrates when compared to proteins with molecular weights greater than 55 kDa. The full list of enriched GO terms is in Table S4 . Figure 1D .
of a single serine to alanine (S452, S366, and S379, respectively) resulted in an almost complete loss of AMPK phosphorylation in these proteins ( Figures 3B-3D ). The mutation of these sites also diminished phosphorylation of PPP1R12C, BAIAP2, and CDC27 by WT-AMPK in vitro ( Figure 3E ), indicating that the specificity of AMPK for these sites is not affected by the gatekeeper methionine to glycine mutation at position 93 in AS-AMPKa2. Thus, S452, S366, and S379, which are part of an AMPK consensus motif, are the major AMPKa2 phosphorylation sites in PPP1R12C, BAIAP2, and CDC27, respectively. PAK2 has several potential AMPK phosphorylation sites ( Figure 3A) . Tandem mass spectrometry analysis of PAK2 phosphorylated in vitro by WT-AMPK revealed that S20, S55, S141, and S197 of PAK2 were phosphorylated in vitro by AMPK (Table S5 ). The mutation of serine 20 to an alanine abolished the phosphorylation of PAK2 by AS-AMPKa2 in cells and by WT-AMPK in vitro, whereas the mutation of the other serines had no or little impact ( Figures 3F and 3G ). Thus, S20, which is part of an AMPK consensus motif, is the major site of AMPK phosphorylation on PAK2.
AMPK Phosphorylates PPP1R12C and PAK2 in Human Cells
We focused on AMPK substrates potentially involved in mitosis. The PPP1R12 family of protein phosphatase regulatory subunits stood out because three members of this family were identified in the screen. PPP1R12C limits the phosphorylation of MRLC (Ito et al., 2004) , a protein involved in mitosis (Komatsu et al., 2000) . Intriguingly, the kinase PAK2, which was also found in the screen, promotes MRLC phosphorylation (Chew et al., 1998; Tuazon and Traugh, 1984) . Thus, AMPK might regulate a network of antagonistic signaling molecules to coordinate mitotic progression.
To determine if AMPK promotes the phosphorylation of PPP1R12C in cells, we generated a phospho-specific antibody to S452 of PPP1R12C (P-S452). This P-S452 antibody was specific to the phosphorylated form of PPP1R12C in that it recognized WT-PPP1R12C in the presence of AMPK but did not recognize the PPP1R12C S452A mutant or WT-PPP1R12C that had not been incubated with AMPK ( Figure S3A ). The P-S452 antibody was also specific to the endogenous phosphorylated form of PPP1R12C in human cells, as shown using siRNA or shRNA to PPP1R12C ( Figure S3B , Figure 4F ). Using this antibody, we showed that phosphorylation of M2-PPP1R12C at S452 was enhanced when 293T cells were treated with the AMPK activator 2DG and decreased when cells were treated with compound C, a chemical inhibitor of AMPK (Zhou et al., 2001 ) ( Figure 4A ). The phosphorylation of endogenous PPP1R12C at S452 in 293T cells was increased in response to 2DG or the highly specific AMPK activator A-769662 (Cool et al., 2006; Goransson et al., 2007; Sanders et al., 2007a) (Figure 4B) . The phosphorylation of M2-PPP1R12C at S452 was also increased in response to 2DG and A-769662 in U2OS cells, and this phosphorylation was reduced when both catalytic subunits of AMPK were knocked down with siRNA ( Figure 4C ). Similar results were observed with endogenous PPP1R12C ( Figure 4D ; Figure S3C ). Importantly, endogenous PPP1R12C phosphorylation at S452 was increased in response to glucose or nutrient starvation ( Figures 4E and 4F) , which are physiological ways of activating AMPK. Similar results were obtained for PAK2 ( Figure S4 ). Together, these results indicate that AMPK phosphorylates endogenous PPP1R12C at S452 and PAK2 at S20 in human cells.
Phosphorylation by AMPK Promotes the Interaction between PPP1R12C and 14-3-3z
We examined the consequences of AMPK phosphorylation on PPP1R12C. PPP1R12A, another regulatory subunit of myosin phosphatase, has been shown to interact with 14-3-3 (Koga and Ikebe, 2008) . We therefore asked if phosphorylation by AMPK affects a potential interaction between PPP1R12C and 14-3-3. Coimmunoprecipitation studies revealed that PPP1R12C interacted with 14-3-3z in 293T cells ( Figure 5A ). Interestingly, the interaction between PPP1R12C and 14-3-3z was abolished by mutation of serine 452 to alanine in PPP1R12C ( Figure 5A ). In contrast, this mutation did not affect the interaction between PPP1R12C and the catalytic phosphatase subunit PP1Cb ( Figure S5A ). The interaction between PPP1R12C and 14-3-3z was decreased when AMPKa1 and a2 were both knocked down ( Figure 5B ). Conversely, the interaction between PPP1R12C and 14-3-3z was increased in response to the specific AMPK activator A-769662 and to glucose starvation ( Figure 5C ). Collectively, these results show that phosphorylation of S452 promotes the interaction between PPP1R12C and 14-3-3z but does not regulate the interaction with the catalytic subunit of the phosphatase ( Figure 5D ). The interaction between PPP1R12C and 14-3-3z may inactivate the PPP1R12C-containing phosphatase complex in vivo.
AMPK Indirectly Regulates MRLC Phosphorylation, in Part via PPP1R12C and PAK2 PPP1R12C and PAK2 directly regulate MRLC phosphorylation at S19 in an opposing manner (Matsumura and Hartshorne, 2008; Tuazon and Traugh, 1984) . We asked whether AMPK affects MRLC phosphorylation in cells. Stimulation of cells with the AMPK activator A-769662 led to an increased phosphorylation of endogenous MRLC at S19, which can be visualized either by an antibody to phospho-S19 or to phospho-T18/S19 ( Figure 5E ). Conversely, knocking down both AMPKa1 and a2 resulted in a modest but significant (p = 0.0012) reduction in M2-MRLC phosphorylation at S19 in 293T cells ( Figures S5B  and S5C ). MRLC was not phosphorylated directly by AMPK in vivo, as shown by in vivo labeling using AS-AMPKa2 (Figure S5D) . These results support the notion that AMPK affects MRLC phosphorylation at S19 indirectly.
(E) In vitro validation of AMPK phosphorylation sites in PPP1R12C, BAIAP2, and CDC27. Kinase assays were carried out as in Figure 2E . (F) In vivo testing of putative phosphorylation sites identified by tandem mass spectrometry for PAK2. Analysis was carried out as described in Figure 1D . (G) In vitro validation of AMPK phosphorylation sites in PAK2. Kinase assay was carried out as in Figure 2E . All panels are representative of two independent experiments. 
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AMPK Phosphorylates Substrates Involved in Mitosis
We next tested if AMPK regulates MRLC phosphorylation via PPP1R12C and PAK2. The increase in MRLC S19 phosphorylation in response to A-769662 was slightly, but reproducibly, reduced in cells expressing the nonphosphorylatable form of PPP1R12C, S452A ( Figure 5F ; Figure S5E ). Expression of a mutant of PAK2 at the AMPK phosphorylation site (S20A) strongly reduced the phosphorylation of MRLC in response to AMPK activation ( Figure 5G ). Phosphorylation by AMPK did not affect PAK2's activity toward MRLC in vitro (M.R.B. and A.B., unpublished data), although it may alter PAK2's accessibility to substrates in cells. Glucose starvation, a physiological way of activating AMPK, led to an increase in the phosphorylation of endogenous AMPK, PPP1R12C, PAK2, and MRLC ( Figure 4E ). Together, these data suggest that AMPK indirectly regulates MRLC phosphorylation in part by phosphorylating PPP1R12C and PAK2.
AMPK Activity and PPP1R12C Phosphorylation Are High in Mitotic Cells
Given the enrichment in AMPK substrates for proteins involved in mitosis, we examined the phosphorylation of endogenous AMPK, PPP1R12C, and PAK2 throughout mitosis. U2OS cells were synchronized with the prometaphase blockers monastrol or nocodazole, and cells were released from the block for different lengths of time. Phosphorylation of AMPK at T172 was high in prometaphase of mitosis and decreased 1 hr after release from the monastrol or nocodazole block ( Figure 6A ; Figures S6A and S6B) . Phosphorylation of PPP1R12C at S452 was also high in prometaphase and tended to decrease 1 hr after the release from the monastrol or nocodazole block, before significantly increasing at the end of mitosis ( Figure 6A ; Figures  S6A and S6B ). In contrast, phosphorylation of PAK2 at S20 was not significantly altered during mitotic progression (Figure 6A ; Figures S6A and S6B) .
To independently follow AMPK activity in mitosis, we used fluorescence resonance energy transfer (FRET) in live cells with a fluorescence reporter for AMPK activity, AMPKAR (Tsou et al., 2011) . AMPKAR fluorescence reached a peak just before U2OS cells divide ( Figure 6B ), indicating that AMPK is highly active in the early phases of mitosis. The levels of AMPK activity slightly decreased as U2OS cells underwent cytokinesis (Figure 6B) . Similar results were observed in other cell types ( Figures  S6C and S6D) . Together, these results indicate that AMPK activity and the phosphorylation of PPP1R12C are high in mitotic cells and decrease as cells progress through mitosis.
Perturbation of AMPK Activity Impairs Mitosis Progression
To test the function of AMPK activity in mitosis, we acutely perturbed AMPK activity after synchronizing cells in mitosis and counted the number of multinucleated cells. Compound C, an inhibitor of AMPK, led to a significant increase in the number of multinucleated cells, similar to BTO-1, an inhibitor of the mitotic kinase Polo-like kinase (PLK) ( Figure 6C, Figure S7A ). In contrast, an inhibitor of PI3K (LY-294002) had no effect on the number of multinucleated cells ( Figure 6C) . Because compound C has other targets in addition to AMPK (Bain et al., 2007; Vogt et al., 2011) , we used alternative approaches to perturb AMPK. U2OS cells expressing shRNA to both AMPKa1 and AMPKa2 exhibited a slight increase in multinucleated cells at some time points after release from a mitotic block, although they did not display an overall increase in multinucleated cells ( Figure S7B ; B.E.S. and A.B., unpublished data). Interestingly, acutely activating AMPK with A-769662, a highly specific activator of AMPK, significantly increased the number of multinucleated cells ( Figure 6C ). Activating AMPK with metformin has also been found to increase the number of multinucleated cells (Vazquez-Martin et al., 2009b) . These observations are reminiscent of what has been shown for important regulators of mitosis (e.g., Mad2, PLK), whose inhibition or activation results in mitotic defects (Brennan et al., 2007; Conn et al., 2000; Michel et al., 2004; Sotillo et al., 2007) . Collectively, these experiments suggest that proper AMPK activity is important for mitotic progression.
AMPK Phosphorylation Site in PPP1R12C Affects Mitotic Progression
We asked if the regulation of PPP1R12C by AMPK is important for mitosis completion. U2OS cells stably expressing PPP1R12C S452A had a significant increase in the percentage of multinucleated cells compared to cells expressing WT-PPP1R12C ( Figure S7C ; Figure 6D ) and to cells expressing the empty vector ( Figure S7D ). These results suggest that the mutation of the AMPK phosphorylation site in PPP1R12C results in defects in mitotic progression and cytokinesis. WT PPP1R12C also led to an increase in the percentage of multinucleated cells, possibly because overexpressed WT PPP1R12C may no longer be phosphorylated by endogenous AMPK and may act as a dominant negative. In contrast, expression of WT or S20A PAK2 did not result in an increase in multinucleated cells compared to control cells ( Figure S7E) . Thus, the phosphorylation of PPP1R12C by AMPKa2 appears to be more important for proper cytokinesis than phosphorylation of PAK2. Interestingly, cells expressing S452A PPP1R12C also had an overall slight, but significant, increase in the percentage of cells in anaphase with lagging chromosomes compared to cells expressing WT PPP1R12C (Figures S8A and S8B) , which is likely a result of defects in chromosomal segregation. Thus, AMPK phosphorylation of PPP1R12C might coordinate chromosomal segregation and cytokinesis. , and PAK2 in U2OS cells synchronized by thymidine followed by monastrol block and collected at different time points after release from the block (blue bar). Cell lysates were analyzed by western blot. (B) AMPK FRET signal is high when cells enter mitosis and starts to decrease around the time the cells initiated cytokinesis in U2OS cells expressing AMPKAR, a fluorescent reporter for AMPK activity. AMPK activity was measured at 10 min intervals. Red, increased AMPK activity. (C) U2OS cells were synchronized by thymidine followed by monastrol block, and chemicals were added 1.5 hr after the release from the monastrol block (blue bar) and replating of mitotic cells. Cells were fixed 4.5 hr after the addition of chemicals. The number of multinucleated cells was normalized to the number observed in nontreated control cells for each experiment. Means ± SEM of three independent experiments are shown, except for the LY-294002 condition, which represents two independent experiments. *p < 0.05 by one-way ANOVA analysis. ns, not statistically significant. (D) U2OS cells expressing WT or S452A PPP1R12C were synchronized by thymidine block. Cells were fixed at the indicated time after release from the block (blue bar). Percentage of multinucleated cells in each condition is shown. Means ± SEM for three independent stainings of a single synchronization experiment. *p < 0.05, **p < 0.01, ***p < 0.001 by two-way ANOVA, with Bonferroni post hoc tests. (E) AMPK directly phosphorylates a number of substrates involved in coordinating different aspects of mitosis.
Our findings indicate that AMPKa2, a critical energy-sensing protein kinase, directly phosphorylates a series of substrates enriched for proteins involved in mitosis completion and chromosomal segregation. AMPK activity and the phosphorylation of one of its substrates, PPP1R12C, are elevated in mitosis. Altering AMPK activity during mitosis impairs mitotic completion. Cells expressing a mutant of PPP1R12C that can no longer be phosphorylated by AMPK also exhibit mitotic defects. Importantly, the residue phosphorylated by AMPK in PPP1R12C is not part of a consensus for the other kinases targeted by compound C or for well-known mitotic kinases (e.g., PLK, CDK1). Taken together, these data support the notion that AMPK regulates mitotic completion.
DISCUSSION
The chemical genetic screen presented here provides a rapid and physiological means of identifying direct in vivo substrates of a protein kinase in cells, which could be applied to other kinases. Our screen was performed in gently permeabilized cells, thus preserving, at least in part, the physiological content of cells. A potential limitation of this screen is that it did not identify all of the previously known AMPK substrates (e.g., TSC2, FOXO3). Improved immunoprecipitation efficiency with the thioP antibody or the use of a peptide capture approach (Blethrow et al., 2008) should help the identification of low-abundant and low molecular weight substrates. Another limitation is that the screen was performed in cells overexpressing the ASAMPKa2, which could lead to artifactual phosphorylation. However, independent confirmation of the phosphorylation of two endogenous substrates (PPP1R12C and PAK2) in cells supports the notion that this chemical genetic approach is a valid way of identifying physiologically relevant substrates of a protein kinase.
While previously known substrates of AMPK have largely implicated this kinase in metabolism, G1 arrest, and transcriptional regulation, the substrates identified here show a significant enrichment for proteins involved in the regulation of mitosis. Phosphorylation of PPP1R12C at the AMPK site appears to be important for the normal completion of mitosis and chromosomal segregation in mammalian cells. We do not rule out the possibility that the effects of AMPK activity on cytokinesis are dependent on substrates other than PPP1R12C or that the effects of phosphorylation of S452 of PPP1R12C on mitosis are dependent on other kinases. For example, the network of AMPK substrates involved in mitosis may extend to APC1 and CDC27, two components of the anaphasepromoting complex identified in our screen. Our results are consistent with the G2/M arrest observed in several cell types lacking AMPK, in Drosophila and mice (Bettencourt-Dias et al., 2004; Dasgupta and Milbrandt, 2009; Gwinn et al., 2008) , the defects in chromosomal segregation in Drosophila larvae lacking AMPK (Lee et al., 2007) , and the observation that AMPK is highly phosphorylated at the mitotic apparatus in cells (Vazquez-Martin et al., 2009a , 2009c . Our results further extend prior studies by proposing a mechanism of action for AMPK in the control of mitosis. Thus, AMPK may control a network of proteins involved in coordinating various aspects of mitotic completion, including anaphase and cytokinesis.
Energy deprivation, by regulating AMPK, could promote the completion of previously initiated mitosis to allow the cell to arrest at the G1/S checkpoint and await more favorable nutrient conditions. Alternatively, AMPK could play a role in mitosis regardless of the energy status of the cell. In fact, AMPK phosphorylation has been shown to increase in mitosis independently of the energy status of the cell (Vazquez-Martin et al., 2009a) , and the percentage of multinucleated cells did not appear to change when cells were deprived of glucose (M.R.B. and A.B., unpublished data). Phosphorylation of substrates involved in orchestrating mitosis and cytoskeletal rearrangements by AMPK could result in coordinating AMPK activity with other cellular fates tightly associated with the birth of new cells, such as polarity and migration. Coordinated completion of mitosis, polarization, and migration by AMPK could be critical for a number of physiological functions, including stem cell homeostasis, and for preventing pathological conditions, such as cancer.
EXPERIMENTAL PROCEDURES
Chemical Genetic Screen for AMPK Substrates in Cells 293T cells (2 3 10 6 cells/10 cm dish) were transfected with 6.67 mg of M2-WT-AMPKa2 or AS-AMPKa2, 6.67 mg HA-AMPKb1, and 6.67 mg HA-AMPKg1 using the calcium phosphate method. Twenty-five 10 cm plates were used for each condition. Forty-eight hours after transfection, the cells were incubated for 2 hr in serum-free DMEM, prior to stimulation with 100 mM 2DG for 5 min. Following stimulation, 500 ml of phosphorylation buffer (20 mM HEPES [pH 7.3], 100 mM KOAc, 5 mM NaOAc, 2 mM MgOAc 2 , 1 mM EGTA, 10 mM MgCl 2 , 0.5 mM DTT, 5 mM creatine phosphate [Calbiochem] , 57 mg/ml creatine kinase [Calbiochem] , 30 mg/ml digitonin, 5 mM GTP, 0.1 mM ATP, 0.1 mM N 6 -[phenethyl] ATPgS, 0.45 mM AMP, 13 phosphatase inhibitor cocktail I and II [Sigma] , and 13 complete protease inhibitors, EDTA-Free [Roche]) was added. After shaking gently for 20 min at room temperature, the cells for each condition were pooled and EDTA was added to a concentration of 20 mM. The cells were then sonicated six times at 4.0 W for 30 s, and the cell pellets were removed by centrifugation. P-nitrobenzyl mesylate (PNBM, Epitomics) was added to the lysates to a final concentration of 2.5 mM, and the samples were then incubated for 1 hr at room temperature. PNBM was removed, and samples were exchanged onto RIPA buffer (100 mM Tris [pH 8], 300 mM NaCl, 2% NP-40, 0.2% SDS, and 20 mM EDTA) using PD-10 columns (Amersham). The protein fractions were then precleared by incubation with protein G agarose beads (Sigma) for 3 hr at 4 C. The precleared extracts were incubated with protein G agarose coupled to the thioP antibody and incubated at 4 C overnight. The beads were washed five times in RIPA buffer, and the bound proteins were eluted with SDS sample buffer. Proteins were resolved by SDS-PAGE and visualized by staining with colloidal blue (Invitrogen).
Mitosis Assay on Stable Cell Lines U2OS cells stably expressing empty vector, M2-PPP1R12C (WT or S452A), or M2-PAK2 (WT or S20A) were plated at 40% confluence and blocked with thymidine (Sigma, 2.5 mM) for 18 hr followed by release from the block by washing twice in fresh media. Cells were fixed in 4% paraformaldehyde at various time points following release and costained with DAPI and the DM1A antibody to stain microtubules or with wheat germ agglutinin (Alexa Fluor 594). The percentage of multinucleated cells was determined for each condition using fluorescence microscopy by counting at least 300-400 cells per condition. A cell was considered multinucleated when it contained more than one nucleus and there was no visible membrane separation between nuclei.
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